Everlaan Organics Inc · 66-41 · CANADA
For Everlaan Organics Inc · 66-41 · CANADA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is CANADA; product is Joint Pain Relief | Muscle Pain Relief | Muscle Pain Relief | Joint Pain Relief | Muscle Pain Relief | Joint Pain Relief; product code is 62 G - - 99 Anti-Inflammatory N.E.C. | 62 G - - 99 Anti-Inflammatory N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. | 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 06/30/2025; address is 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA, verified against its source on 2026-09-16.
- Firm
- Everlaan Organics Inc verified
- Import alert
- 66-41
- Import alert name
- Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
- Country
- CANADA verified
- Address
- 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA verified
- Date published
- 06/30/2025 verified
- Product code
- 62 G - - 99 Anti-Inflammatory N.E.C. | 62 G - - 99 Anti-Inflammatory N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 62 U - - 99 Anti-Tussive/Cold N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. each item verified
- Product
- Joint Pain Relief | Muscle Pain Relief | Muscle Pain Relief | Joint Pain Relief | Muscle Pain Relief | Joint Pain Relief each item verified
- FDA notes
- Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. | Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. each item verified
What the source says
Everlaan Organics Inc Date Published : 06/30/2025 17220 Heather Dr Unit 106 , Surrey, British Columbia CANADA 62 G - - 99 Anti-Inflammatory N.E.C. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 G - - 99 Anti-Inflammatory N.E.C. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 U - - 99 Anti-Tussive/Cold N.E.C. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 62 U - - 99 Anti-Tussive/Cold N.E.C. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 06/30/2025 Desc: Muscle Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 06/30/2025 Desc: Joint Pain Relief Notes: Product appears to be unapproved new drug in violation of section 505(a) of the FD&C Act. New drugs may not be legally marketed in the U.S. without prior approval from the FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)].
— accessdata.fda.gov, retrieved 2026-09-15
Source
- accessdata.fda.govhttps://www.accessdata.fda.gov/cms_ia/importalert_190.html
This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.